# Wegovy pill vs injection: what changes when you swallow it

> Source: https://peptidewellnessusa.com/peptides/compare/wegovy-pill-vs-injection/
> Compare · GLP-1
> By PeptideWellness Editorial Team · Medically reviewed by Ksenia Petrushkina, PA-C, MPAS · Updated November 11, 2026 · 6 min read

The Wegovy tablet, approved in December 2025, is 25 mg taken every morning on an empty stomach. The injection is 2.4 mg once a week. The tablet needs ten times the milligrams because almost none of it is absorbed, and in its trial it produced 13.6% weight loss against the injection's 14.9% in a separate trial.

Wegovy has been an injection since 2021. In December 2025 FDA approved a tablet: 25 mg of the same molecule, taken every morning [1]. The two are not interchangeable milligram for milligram, and the tablet comes with rules the injection does not have.

The short version: the injection is 2.4 mg once a week, the tablet is 25 mg once a day, and the reason for that gap is absorption. In their separate trials, the tablet produced 13.6% weight loss over 64 weeks and the injection 14.9% over 68 weeks [1][2].

## The two products

|  | Injection | Tablet |
| --- | --- | --- |
| How often | Once a week | Once a day |
| Maintenance dose | 2.4 mg, with 7.2 mg available above it | 25 mg |
| Getting there | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg, four weeks per step | 1.5 → 4 → 9 → 25 mg, 30 days per step |
| Rules | Any time of day, with or without food; rotate sites | Morning, empty stomach, up to 4 oz of water, swallow whole, then nothing for 30 minutes |
| Approved for | Weight in adults and children 12 and over, heart-risk reduction, and MASH with fibrosis | Weight and heart-risk reduction, adults only |
| Storage | Refrigerated pens | Tablets at room temperature |

Source: the Wegovy label [1].

## Why 25 mg against 2.4 mg

Semaglutide is a peptide, and the digestive system destroys peptides. The approved oral form gets around that with an absorption enhancer, salcaprozate sodium, mixed into the tablet. Even with it, only about 0.4% to 1% of a swallowed dose reaches the blood [3].

That is also why the tablet's rules exist. Food, other drinks and other pills all cut absorption further, which is what the empty stomach, the four ounces of water and the 30-minute wait are protecting. The tablet must be swallowed whole: splitting, crushing or chewing it breaks the formulation [1].

The injection skips all of this. Delivered under the skin, nearly all of the dose reaches the blood, and the weekly schedule follows from how long semaglutide lasts in the body.

## What the trials found

The tablet's trial, OASIS 4, randomized 307 adults with obesity, or overweight with a weight-related condition and no diabetes, two to one to 25 mg of oral semaglutide or placebo, with lifestyle support, over 71 weeks. At week 64, average weight was down 13.6% against 2.2% on placebo, a difference of 11.4 percentage points [2]. On the label's figures, 76.3% lost at least 5% of their weight, 59.8% at least 10%, 47% at least 15% and 27.9% at least 20%, against 31.3%, 14.4%, 5.5% and 3.1% on placebo [1].

The injection's main trial ran 68 weeks in a similar population and produced 14.9% against 2.4% [1].

The two trials were not run against each other. Different sizes, different lengths, different participants. What they support is that the tablet is in the same range as the injection, not that one beat the other.

## Side effects

The label says the types and frequency of common adverse reactions with the 25 mg tablet were similar to those with the injection: nausea, diarrhea, vomiting and constipation at the top of the list [1]. In OASIS 4, 74.0% of people on the tablet had a gastrointestinal adverse event against 42.2% on placebo [2].

Discontinuation looks similar too. In the tablet trial, 6.9% stopped because of side effects against 5.9% on placebo, of which stomach problems were 3.4% against 2% [1]. For the injection it was 6.8% against 3.2% [1].

Both forms carry the same warnings, including the boxed warning about thyroid C-cell tumors in rodents. The full list is on our [GLP-1 side effects](https://peptidewellnessusa.com/learn/glp-1-side-effects/) page.

## Switching

The label allows movement in both directions [1]:

- **Injection to tablet.** One week after the last 2.4 mg injection, start the 25 mg tablet daily.
- **Tablet to injection.** The day after the last tablet, start 2.4 mg weekly. For anyone who did not tolerate the 25 mg tablet, the label suggests considering the 1.7 mg injection instead.

Neither switch is something to do on your own: both are prescription changes, and the tablet strengths are not swappable with the Ozempic or Rybelsus tablets, which are diabetes products at entirely different doses [1].

## Cost

Novo's own prices differ by form. The tablets are $149 a month at 1.5 mg, $199 at 4 mg and $299 at the 9 and 25 mg doses, where a month is a bottle of 30 tablets. The pens are $199 a month for the first two fills at the starting doses, through the end of 2026, and $349 after that for any dose up to 2.4 mg [4].

The Medicare GLP-1 Bridge covers both forms at $50 a month for eligible Part D members through 2027 [5]. [How to get a GLP-1](https://peptidewellnessusa.com/learn/how-to-get-a-glp-1/) covers the routes in full.

## Which one

The tablet suits people who will not inject, or who travel and would rather not carry refrigerated pens. It costs a daily routine: morning, empty stomach, 30 minutes before coffee or any other medicine. Skipping that routine is not a small deviation, since it is what gets the drug absorbed at all.

The injection suits people who prefer one action a week and no food rules, and it is the form with the children's indication, the liver indication and the higher 7.2 mg strength if 2.4 mg is not enough [1].

What neither of them is: a compounded "oral semaglutide" bought from a telehealth seller. Those are not this product and have no human absorption data at all, as our page on [sublingual semaglutide](https://peptidewellnessusa.com/learn/sublingual-semaglutide/) sets out.

## Frequently asked

### Is the Wegovy pill as effective as the injection?

In separate trials the tablet gave 13.6% average weight loss over 64 weeks and the injection 14.9% over 68 weeks. They have never been compared head to head [1][2].

### Why is the Wegovy pill 25 mg when the injection is 2.4 mg?

Because only about 0.4% to 1% of a swallowed dose reaches the blood, even with the absorption enhancer in the tablet [3].

### Can I take the Wegovy tablet with food or coffee?

No. It goes on an empty stomach in the morning with no more than four ounces of water, and nothing else to eat, drink or swallow for 30 minutes [1].

### Can I switch from the Wegovy injection to the pill?

Yes, with a prescription: one week after the last 2.4 mg injection, start the 25 mg tablet. The reverse switch starts the day after the last tablet [1].

### Are the Wegovy tablet and Rybelsus the same?

No. Rybelsus and the Ozempic tablets are for type 2 diabetes, at 3 to 14 mg and 1.5 to 9 mg. The Wegovy tablet is for weight, at up to 25 mg [1].

### Does the pill cost less than the injection?

At Novo's own prices, the 25 mg tablet is $299 a month and the 2.4 mg pen $349 after the introductory fills [4].

## References

1. [FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised June 2026: sections 1, 2, 3, 6.1 and 14. DailyMed, read 10 November 2026.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
2. [Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). *N Engl J Med.* 2025;393(11):1077-1087. PMID 40934115.](https://pubmed.ncbi.nlm.nih.gov/40934115/)
3. [FDA. Rybelsus (semaglutide) tablets, prescribing information, NDA 213051, sections 2.1 and 12.3.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98)
4. [NovoCare. Wegovy cost, coverage and savings. Read 10 November 2026.](https://www.novocare.com/patient/medicines/wegovy.html)
5. [Medicare.gov. Weight loss drugs: the Medicare GLP-1 Bridge. Read 10 November 2026.](https://www.medicare.gov/coverage/weight-loss-drugs)

## Medical disclaimer

This page is informational and is not medical advice. It compares two forms of one approved drug; it cannot tell you whether semaglutide is appropriate for you. Wegovy carries a boxed warning for thyroid C-cell tumors and is not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Which form, which dose and whether to switch are decisions for a prescriber.